News

Taro Pharmaceutical Industries (Taro) has initiated phase I clinical trials in Canada with T2007, the second in the company’s class of proprietary non-sedating barbiturate compounds to be approved

Cangene has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) regarding the immunoprophylaxis indication of its ImmunoGam (Human Hepatitis B Immunoglobulin).

Thallion Pharmaceuticals (Thallion) has signed a binding Letter of Intent (LOI) with LFB Biotechnologies (LFB) for the development of Shigamabs, Thallion’s product candidate for the treatment of Shiga

PolyMedix has completed the first two segments of a phase 1B clinical safety study with its antibiotic drug candidate, PMX-30063. PMX-30063 is small-molecule mimetic of host defense proteins

Ista has submitted a supplemental New Drug Application (sNDA) to the FDA for bromfenac ophthalmic solution as a treatment for ocular inflammation and pain following cataract surgery. Ista

Amgen has received a positive opinion for the marketing authorisation of Prolia (denosumab) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

Boehringer Ingelheim and Pfizer have received FDA approval for Spiriva HandiHaler (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

McNeil Consumer Healthcare (McNeil), division of McNEIL-PPC, has been expanding its voluntary recall to include all available product lots of Tylenol arthritis pain caplet 100 count bottles, with

The United States Patent and Trademark Office (USPTO) has determined that US Patent No. 6444673, which is a composition of matter patent that covers Sepracor’s human drug product,